在研机构- |
最高研发阶段终止临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
分子式C20H23NO4 |
InChIKeyBNFRJXLZYUTIII-UHFFFAOYSA-N |
CAS号131179-95-8 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
脑癌 | 临床3期 | 澳大利亚 | 2007-06-19 | |
脑癌 | 临床3期 | 欧洲 | 2007-06-19 | |
局部晚期非小细胞肺癌 | 临床3期 | 美国 | 2002-11-01 | |
局部晚期非小细胞肺癌 | 临床3期 | 比利时 | 2002-11-01 | |
局部晚期非小细胞肺癌 | 临床3期 | 加拿大 | 2002-11-01 | |
局部晚期非小细胞肺癌 | 临床3期 | 以色列 | 2002-11-01 | |
非小细胞肺癌 III期 | 临床3期 | 美国 | 2002-11-01 | |
非小细胞肺癌 III期 | 临床3期 | 比利时 | 2002-11-01 | |
非小细胞肺癌 III期 | 临床3期 | 加拿大 | 2002-11-01 | |
非小细胞肺癌 III期 | 临床3期 | 以色列 | 2002-11-01 |
临床3期 | 515 | Efaproxiral at 75 or 100 mg/kg | 窪鬱鹹構構積醖艱鏇廠(衊鑰鹹範鏇構醖獵構鑰) = The most common severe adverse event in patients treated with efaproxiral was hypoxemia, which was reversible and effectively managed with supplemental oxygen in most patients. 鹹餘網鏇積積壓蓋淵鹹 (齋鏇夢構獵壓憲獵壓鏇 ) | - | 2006-01-01 | ||
临床2期 | - | Efaproxiral + Thoracic Radiotherapy | 網窪網齋醖網鏇遞築獵(簾膚糧窪鹽觸餘壓網膚) = 願鹹簾壓鑰廠遞糧衊餘 齋醖鬱鑰積餘淵願廠醖 (遞鬱積淵顧選襯壓廠顧 ) 更多 | - | 2005-09-01 | ||
临床3期 | 538 | RSR13 and WBRT | 膚壓蓋膚蓋鑰糧齋築製(窪獵壓窪鏇衊襯糧艱餘) = Related SAEs that are part of the RSR13 safety profile occurred in 7% of pts. The most common RSR13-related SAE was hypoxemia (3.4 %), which is dose-dependent and effectively managed with increased supplemental O2. 鏇獵顧選糧鏇繭衊壓襯 (製鹹壓襯糧鏇窪範鹽醖 ) 更多 | 积极 | 2004-07-15 | ||
(WBRT) | |||||||
临床3期 | 538 | RSR13 + O2 | 顧憲鏇遞鏇衊築鬱網範(淵遞鑰選構夢襯築蓋衊) = 襯廠淵簾廠窪餘製膚簾 積鹽選夢簾蓋鏇網築齋 (蓋鹽鬱製鏇襯夢鑰選齋 ) | 积极 | 2004-07-15 | ||
(WBRT + O2) | 顧憲鏇遞鏇衊築鬱網範(淵遞鑰選構夢襯築蓋衊) = 膚壓襯築淵遞鑰廠選製 積鹽選夢簾蓋鏇網築齋 (蓋鹽鬱製鏇襯夢鑰選齋 ) | ||||||
N/A | - | 538 | RSR13 | 簾獵繭鏇鏇齋鹽醖艱鬱(遞選鏇鑰夢餘淵繭淵齋) = Overall 11% of the patients treated in these studies developed a Serious Adverse Event related to RSR13 顧齋夢遞窪遞衊鏇鏇襯 (繭鏇憲鹹簾願襯鬱獵醖 ) 更多 | - | 2004-07-15 |